Prognostic value of microRNAs in cervical carcinoma: a systematic review and meta-analysis

Shengkang Dai; Yan Lu; Ying Long; Yuehua Lai; Ping Du; Nan Ding; Desheng Yao

doi:10.18632/oncotarget.9294

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Prognostic value of microRNAs in cervical carcinoma: a systematic review and meta-analysis

Shengkang Dai, Yan Lu, Ying Long, Yuehua Lai, Ping Du, Nan Ding and Desheng Yao _

PDF | HTML | How to cite

Oncotarget. 2016; 7:35369-35378. https://doi.org/10.18632/oncotarget.9294

Metrics: PDF 2108 views | HTML 2469 views | ?

Abstract

Shengkang Dai1, Yan Lu1, Ying Long1, Yuehua Lai1, Ping Du1, Nan Ding1, Desheng Yao1

1Department of Gynecologic Oncology, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi, China

Correspondence to:

Desheng Yao, e-mail: [email protected]

Keywords: microRNA, prognosis, cervical carcinoma, meta-analysis

Received: December 08, 2015 Accepted: April 11, 2016 Published: May 11, 2016

ABSTRACT

This systematic review is written to investigate the outcome of cervical cancer. A comprehensive search of PubMed and EMBASE was performed to identify eligible studies. Nineteen studies from thirteen articles with a total of 1,310 participants were included in this meta-analysis. Overall survival (OS), disease-free survival (DFS), and recurrence-free survival (RFS) as a prognosis for cervical cancer were extracted and calculated, if available. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using STATA (version 12.0), resulting in the pooled HRs 0.70 (95% CI: 0.51–0.97) for OS, 1.02 (95% CI: 0.53–1.98) for DFS, and 0.56 (95% CI: 0.40–0.77) for RFS. The results indicated that cervical cancer patients with decreased microRNA expression were associated with shorter OS and RFS. It suggested that microRNAs might be promising markers for predicting the survival rate of cervical cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 9294

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Prognostic value of microRNAs in cervical carcinoma: a systematic review and meta-analysis

Abstract